Study S001878

A Dose Block-randomized, Double-blind, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM11260C After Subcutaneous Administration in Healthy Male Subjects

ClinicalTrials.gov record

Registration

Registration: NCT01093729
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: TRIPLE
Status: COMPLETED
Enrollment: 41
Start: 2010-02
Primary completion: 2010-10
Lead sponsor: Hanmi Pharmaceutical Company Limited
Conditions: Healthy
Interventions: DRUG:HM11260C
Results posted: FALSE

Registered primary outcomes

Safety [1, 2, 3, 4, 5, 7, 9, 16, 22, 30, 36, 43, 57, 84 Day]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.